Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

An expert discusses how current immune thrombocytopenia (ITP) treatments such as corticosteroids, rituximab, and fostamatinib ...

What Is Wayrilz, and Why Does It Matter? Wayrilz (rilzabrutinib) is a new oral medicine for adults with a long-lasting blood clotting disorder known as chronic immune thrombocytopenia (ITP) who ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).